Comparison of supercritical fluid chromatography and reverse phase liquid chromatography for the impurity profiling of the antiretroviral drugs lamivudine/BMS-986001/efavirenz in a combination tablet

Journal of Pharmaceutical and Biomedical Analysis

Volumn 78-79, Issue , 2013, Pages 243-251

  Alexander, A J ^a   Zhang, L ^a   Hooker, T F ^a,b   Tomasella, F P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

API; Nucleoside reverse transcriptase inhibitors; Pharmaceutical impurity profiling; RPLC; Supercritical fluid chromatography

Indexed keywords

AMMONIUM ACETATE; ANTIRETROVIRUS AGENT; BMS 986001; EFAVIRENZ; LAMIVUDINE; METHANOL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); DRUG DEGRADATION; DRUG IMPURITY; DRUG SOLUBILITY; ELUTION; HIGH TEMPERATURE; PH; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVERSED PHASE LIQUID CHROMATOGRAPHY; SIGNAL NOISE RATIO; SUPERCRITICAL FLUID CHROMATOGRAPHY; TABLET;

ANTI-HIV AGENTS; BENZOXAZINES; CHROMATOGRAPHY, LIQUID; CHROMATOGRAPHY, SUPERCRITICAL FLUID; DRUG COMBINATIONS; HYDROGEN-ION CONCENTRATION; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS; TABLETS; TEMPERATURE; THYMIDINE;

EID: 84875239907     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.02.019     Document Type: Article

References (36)

1. Flexner C. HIV drug development: the next 25 years. Nat. Rev. Drug Discov. 2007, 6:959-966.
2. Dutschman G.E., Grill S.P., Gullen E.A., Haraguchi K., Takeda S., Tanaka H., Baba M., Yung-Chi Cheng Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob. Agents Chemother. 2004, 48:1640-1646.
3. Jayadev S., Manikanta K., Sundar B.S., Rao V.J. Simultaneous estimation of lamivudine and tenofovir disoproxil fumarate by RP-HPLC in the pharmaceutical dosage form. Asian J. Chem. 2011, 23:1683-1686.
4. Venkatesh P., Smiley L., Mahesh D. Simultaneous estimation of zidovudine and lamivudine tablets by RP-HPLC method. Int. J. Chem. Tech. Res. 2011, 3:376-380.
5. Sarkar M., Khandavilli S., Panchagnula R. Development and validation of RP-HPLC and ultraviolet spectrophotometric methods of analysis for the quantitative estimation of antiretroviral drugs in pharmaceutical dosage forms. J. Chromatogr. B 2006, 830:349-354.
6. Soares M.F.L.R., Soares-Sobrinho J.L., da Silva K.E.R., Rolim L.A., Alves L.D.S., Rolim-Neto P.J. Simultaneous determination of antiretroviral zidovudine, lamivudine and efavirenz by RP HPLC-DAD. Lat. Am. J. Pharm. 2011, 30:273-280.
7. Jayaseelan S., Ganesh S., Rajasekar M., Sekar V., Perumal P. A new analytical method development and validation for the simultaneous estimation of lamivudine and stavudine in tablet dosage form by RP-HPLC method. Int. J. Pharm. Tech. Res. 2010, 2:1539-1542.
8. Checa A., Oliver R., Hernández-Cassou S., Saurina J. Reversed-phase liquid chromatographic method with spectrophotometric detection for the determination of antiretroviral drugs. Anal. Chim. Acta 2008, 616:85-94.
9. Patel U.M., Rao R.N. Development and validation of a stability indicating RP-HPLC method for simultaneous determination of Lamivudine and Stavudine in combined dosage forms. J. Chem. Pharm. Res. 2011, 3:200-211.
10. Joshi A., Adeyeye C. Reversed phase LC-UV method development and validation for simultaneous determination of three antiretrovirals: lamivudine, zidovudine, nevirapine and possible degradants in a fixed dose pharmaceutical product. J. Pharm. Tech. Drug Res. 2012, http://www.hoajonline.com/journals/jptdr/content/pdf/4.pdf2 (accessed 20.12.12).
11. Venkata Reddiah C.H., Rama Devi P., Mukkanti K., Katari S. Reversed phase LC-UV method development and validation for simultaneous determination of three antiretrovirals: lamivudine, zidovudine, nevirapine and possible degradants in a fixed dose pharmaceutical product. Int. J. Pharm. Phytopharm. Res. 2012, 1:247-256.
12. Pendelaa M., Van Gyseghemb E., Van den Mooter G., Baertc L., Rosierc J., Hoogmartensa J., Adamsa E. Development of a liquid chromatographic assay for an anti-HIV tablet containing lamivudine, zidovudine and TMC278.HCL. J. Pharm. Biomed. Anal. 2009, 49:508-512.
13. USP monograph for lamivudine. (accessed 20.12.12). http://www.pharmacopeia.cn/v29240/usp29nf24s0_m44243.html.
14. USP monograph for efavirenz. (accessed 20.12.12). https://www.usp-mc.org/monographs/efavirenz-1-0.
15. USP monograph for lamivudine and stavudine tablets. (accessed 20.12.12). http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/pendingStandards/lamivudineStavudineTabletsm2746.pdf.
16. International Pharmacopoeia for lamivudine. (accessed 20.12.12). http://www.who.int/medicines/publications/pharmacopoeia/QAS_124rev2_Lamivudine.monoFINAL.pdf.
17. International Pharmacopoeia for efavirenz. (accessed 20.12.12). http://www.who.int/medicines/publications/pharmacopoeia/QAS_145rev2_Efavirenz_monoFINAL07.pdf.
18. n. J. Pharm. Biomed. Anal. 2009, 49:55-63.
19. Montgomery E.R., Edmanson A.L., Cook S.C., Hovsepian P.K. Development and validation of a RPLC method for analysis of efavirenz and its related substances in the drug substance and in a capsule formulation. J. Pharm. Biomed. Anal. 2001, 25:267-284.
20. Weissburg R.P., Montgomery E.R., Junnier L.A., Segretario J., Cook S., Hovsepian P.K. Investigation of critical factors for the resolution of SR695, a key impurity, from efavirenz in the RP assay of efavirenz dosage forms. J. Pharm. Biomed. Anal. 2002, 28:45-56.
21. Hamrapurkar P.D., Patil P.S., Phale M.D., Shah N., Pawar S.B. Optimization and validation of RPLC stability indicating method for determination of efavirenz and its degradation products. Int. J. Applied Sci. Eng. 2010, 8:144-165.
22. Maurin M.B., Rowe S.M., Blom K., Pierce M.E., Kinetics Mechanism of hydrolysis of efavirenz. Pharm. Res. 2002, 19:517-521.
23. West C., Lesellier E. A unified classification of stationary phases for packed column SFC. J. Chromatogr. A 2008, 1191:21-39.
24. Taylor L.T. Supercritical fluid chromatography. Anal. Chem. 2010, 82:4925-4935.
25. Wang Z., Liu O., Donovan B. The path forward for SFC in the drug development environment-an industrial perspective. Am. Pharm. Rev. 2009, 12:94-99.
26. T.A. Berger, K. Fogelman, Improving Signal-to-Noise Ratio and Dynamic Range in SFC with UV detection, The Peak September on-line edition, LC-GC North America, 2009, pp. 17-33.
27. Berger T.A., Berger B.K. Minimizing UV noise in supercritical fluid chromatography. I. Improving back pressure regulator noise. J. Chromatogr. A 2011, 1218:2320-2326.
28. Alexander A.J., Hooker T.F., Tomasella F.P. Evaluation of mobile phase gradient supercritical fluid chromatography for impurity profiling of pharmaceutical compounds. J. Pharm. Biomed. Anal. 2012, 70:77-86.
29. Alexander A.J. SFC instrument modification to allow greater flexibility in method development by generating mixtures of solvents and modifiers on-line for mobile phase B optimization. Chromatographia 2012, 75:185-1190.
30. Jayaraman K., Alexander A.J., Hu Y., Tomasella F.P. A stepwise strategy employing automated screening and DryLab modeling for the development of robust methods for challenging HPLC separations: a case study. Anal. Chim. Acta 2011, 696:116-124.
31. Corredor C.C., Castoro J.A., Young J. Application of multidimensional screening and analysis and computer simulation software for rapid HPLC method development. J. Pharm. Innov. 2009, 4:121-132.
32. Molnar I. Computerized design of separation strategies by reversed-phase liquid chromatography: development of DryLab software. J. Chromatogr. A 2002, 965:175-194.
33. 2-methanol mobile phase. J. Chromatogr. A 2009, 1216:6441-6450.
34. 2 and water as the polar additive. J. Sep. Sci. 2010, 33:1682-1691.
35. West C., Bouet A., Routier S., Lesellier E. Effects of mobile phase composition and temperature on the SFC enantioseparation of chiral fluoro-oxoindole-type compounds with chlorinated polysaccharide stationary phases. J. Chromatogr. A 2012, http://dx.doi.org/10.1016/j.chroma.2012.09.078.
36. International Conference on Harmonization (ICH) Guideline, Q3A(R2):Impurities in New Drug Substances. (accessed 20.12.12). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Guideline.pdf.